Bryan Cox
Hoofd Techniek/Wetenschap/O&O bij TRISALUS LIFE SCIENCES, INC.
Vermogen: 620 743 $ op 31-05-2024
Profiel
Bryan F.
Cox is currently the Chief Executive Officer at Nephraegis Therapeutics, Inc. and the Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. Previously, he worked as the Director-Integrative Pharmacology at Abbott Laboratories from 1996 to 2013.
Dr. Cox holds a doctorate degree from the University of Iowa and an undergraduate degree from The University of North Carolina at Chapel Hill.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-02-2024 | 86 696 ( 0.32% ) | 620 743 $ | 31-05-2024 |
Actieve functies van Bryan Cox
| Bedrijven | Functie | Begin |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 10-08-2023 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Algemeen Directeur | 01-11-2018 |
Eerdere bekende functies van Bryan Cox
| Bedrijven | Functie | Einde |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01-01-2013 |
Opleiding van Bryan Cox
| University of Iowa | Doctorate Degree |
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
